A Phase 1, Open-label, Non-randomized, Parallel Group, Single-dose Adaptive Study in Adults With Hepatic Impairment and Matched, Healthy Control Participants With Normal Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 25 Sep 2018
At a glance
- Drugs Daprodustat (Primary)
- Indications Anaemia
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 13 Sep 2018 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 12 Jul 2018 Planned End Date changed from 18 May 2018 to 3 Aug 2018.